BioNTech SE BNTX is trading higher Monday morning after the company announced better-than-expected second-quarter financial results.
BioNTech reported quarterly earnings of $12.97 per share, which beat the estimate of $8.91 per share. The company reported quarterly revenue of $6.39 billion, which beat the estimate of $3.84 billion.
BioNTech said that more than 1 billion doses of its BNT162b2 vaccine has been supplied worldwide.
“We and our partner Pfizer Inc PFE have crossed the one billion mark for COVID-19 vaccine doses shipped worldwide. We are proud to have reached this great milestone after only six months and to have made a difference for people with our proprietary mRNA technology," said Ugur Sahin, co-founder and CEO of BioNTech.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, as well as vaccines for infectious diseases, including COVID-19.
Price Action: BioNTech has traded as high as $433.90 and as low as $54.10 over a 52-week period.
At last chek Monday, the stock was up 5.15% at $409.06.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.